-
Novartis GIST Registry
Help Novartis Oncology collect information from doctors on the diagnosis and management of GIST via doctor participation in a GIST Registry. Print a brochure about the GIST Registry to bring to your doctor.
Continue reading -
Sarcoma Awareness Week
The Sarcoma Alliance urges all sarcoma patients to participate in Sarcoma Awareness Week June 11-18, 2006 by doing something on the local level to gain attention for sarcoma. Arthur Beckert prepared a list of possible activites you could do in your community: download the list here. For more information contact the Sarcoma Alliance at info@sarcomaalliance.org […]
Continue reading -
Phase I Clinical Trial of IPI-504
— Novel Treatment Paradigm Has Potential to Address Resistance to Current Targeted Therapies — CAMBRIDGE, Mass., Jan. 10 /PRNewswire/ — Infinity Pharmaceuticals, Inc.today announced the initiation of a second Phase I clinical trial of IPI-504,the company’s Heat Shock Protein 90 (Hsp90) inhibitor and lead investigationalanti-cancer agent. This study, part of the Company’s evolving oncologydevelopment program, […]
Continue reading -
4-year follow-up of Gleevec
At the ASCO Gastrointestinal Cancer Symposium held in late January, 2006, Dr. Charles Blanke presented a poster detailing 4-year follow-up results of the patients in the first randomized Phase II clinical trial of Gleevec for treatment of GIST, known as the B2222 trial. These patients represent the longest ongoing data set about Gleevec used to […]
Continue reading -
Biology of Gastrointestinal Stromal Tumors — Corless et al. 22 (18): 3813 — Journal of Clinical Oncology
Christopher L. Corless, Jonathan A. Fletcher, Michael C. Heinrich From the Oregon Health & Science University Cancer Institute, Department of Pathology, and Division of Hematology and Oncology, Oregon Health & Science University and Veterans Affairs Medical Center, Portland, OR; and Department of Pathology, Brigham & Women’s Hospital, Boston, MA </font /> Address reprint requests to […]
Continue reading -
Study finds new designer drug is potent treatment for chronic myelogenous leukemia
Hybrid targeted therapy effective in treating Gleevec-resistant disease BOSTON–Using rational drug design strategies, investigators atDana-Farber Cancer Institute and Novartis Pharmaceuticals in Basel,Switzerland have created a targeted therapy for chronic myelogenousleukemia (CML) that may ultimately be more effective than Gleevec ®, thecurrent frontline treatment. The researchers report in the Februaryissue of Cancer Cell that the new […]
Continue reading -
FDA Works to Speed the Advent of New, More Effective Personalized Medicines
As part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics, the Food and Drug Administration (FDA) today issued a final guidance titled “Pharmacogenomic Data Submissions.” Pharmacogenomics allows health care providers to identify sources of an individual’s profile of drug response and predict the best possible treatment option […]
Continue reading -
Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 3/2004, under the auspices of ESMO
Below is an informal summary of a consensus summary on GIST treatment by an international group of GIST experts. The consensus conference to develop this guideline was sponsored by the European Society of Medical Oncology (ESMO) with a grant from Novartis. A meeting was held in March 2004 among 41 experts from 12 countries from […]
Continue reading -
Molecular Testing in Patients with Rare Cancer Predicts Response to Gleevec
PORTLAND, Ore. – Patients with gastrointestinal stromal tumors (GIST) who have a particular genetic mutation are more likely to respond to Gleevec (imatinib) than those without the mutation, according to OHSU study results showcased at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO). The results confirm previous observations and provide a […]
Continue reading -
Personalized Medicine Moves Forward
PORTLAND, Ore. – Patients with gastrointestinal stromal tumors (GIST) who have a particular genetic mutation are more likely to respond to Gleevec (imatinib) than those without the mutation, according to OHSU study results showcased at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO). The results confirm previous observations and provide a […]
Continue reading